Adaptimmune

Photo
News

Adaptimmune and TCR2 Agree Merger

Clinical stage biotechs Adaptimmune and TCR2 Therapeutics have agreed to merge, forming what they said would be a “preeminent cell therapy company focused on creating solid tumors” with projected sales of about $27 billion by 2026.

Top-Feature

Special Issue

Circular Plastics Economy
Explore the Future of Plastics

Circular Plastics Economy

This special CHEManager issue explores the industry’s pivotal shift towards a more sustainable, circular plastics value chain. Readers will find expert analysis and real-world solutions for today’s most pressing recycling and regulatory challenges.